DSGN logo

DSGN
Design Therapeutics Inc

396
Mkt Cap
$770.29M
Volume
193,932.00
52W High
$12.84
52W Low
$2.88
PE Ratio
-9.98
DSGN Fundamentals
Price
$12.16
Prev Close
$12.49
Open
$12.50
50D MA
$10.57
Beta
1.62
Avg. Volume
282,414.55
EPS (Annual)
-$1.22
P/B
3.46
Rev/Employee
$0.00
$319.45
Loading...
Loading...
News
all
press releases
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the stock, Marketbeat.com...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year High - What's Next?
Design Therapeutics (NASDAQ:DSGN) Hits New 12-Month High - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Trading Up 6.8% - Still a Buy?
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.8% - Should You Buy...
MarketBeat·4d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Here's What Happened
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - What's Next...
MarketBeat·8d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year High - Here's Why
Design Therapeutics (NASDAQ:DSGN) Hits New 52-Week High - What's Next...
MarketBeat·25d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading Volume - Time to Buy?
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume Increase - Should You Buy...
MarketBeat·25d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group
Jefferies Financial Group started coverage on Design Therapeutics in a research note on Monday. They set a "buy" rating and a $15.00 price target on the stock...
MarketBeat·25d ago
News Placeholder
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program
Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a conference discussion with Leerink Partners' Joe Schwartz, featuring comments from...
MarketBeat·26d ago
News Placeholder
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the company, MarketBeat.com...
MarketBeat·28d ago
News Placeholder
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade
Design Therapeutics (NASDAQ:DSGN) Shares Up 6.7% on Analyst Upgrade...
MarketBeat·1mo ago
<
1
2
...
>

Latest DSGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.